A thyroid-hormone-receptor-beta treatment for eligible steatohepatitis with specified liver fibrosis; current assessment determines suitability.
Profile scope: Resmetirom. Confirm the exact product and route; formulations and combination products are not interchangeable.
Possible side effects
Diarrhea, nausea, itching, abdominal discomfort, dizziness, or constipation may occur.
Serious risks and warning signs
Liver injury and gallbladder-related symptoms require assessment. Jaundice, persistent vomiting, fever, or significant upper-abdominal pain needs prompt contact. Existing liver disease and interactions, including lipid medicines, affect treatment planning.
A question for your healthcare team
Which liver, gallbladder, lipid, and interaction checks are needed to assess benefit and safety?
What to do with this information
Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.
Sources
Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.